Understanding how interleukin-1a affects immune response in cancer treatment
Official title: Release of interleukin-1a as a mediator of immune evasion in cancer
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11046813 · Data updated 2026-11-12
This study is looking at how a substance called interleukin-1 alpha, which is released when cancer cells die, affects the immune system during cancer treatments, with the hope of finding better ways to help patients respond to their therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | December 10, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $568,538 |
| NIH project number | 1R01CA289581-01A1 |
| Project ID | NIH-11046813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing treatment for cancer who may benefit from enhanced immunotherapy approaches.
✕Less likely to help
Patients with cancers that do not involve the immune response or those not receiving standard cancer therapies may not benefit from this research.
What this research studies
This research investigates the role of interleukin-1 alpha in cancer therapies, particularly how its release during cell death can influence the immune response. The study aims to explore how different cancer treatments induce cell death and how this process can either promote or inhibit tumor growth. By examining the mechanisms behind interleukin-1 alpha's effects, the research seeks to identify ways to enhance the effectiveness of existing cancer therapies. Patients may benefit from insights that could lead to improved treatment strategies targeting immune responses.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by improving the immune response against tumors.
How similar studies have gone: Previous research has shown promising results in targeting immune responses in cancer therapy, suggesting potential for success in this approach.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Ruffell, Brian — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Ruffell, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.